The purpose of this post-marketing surveillance is to identify problems and questions regarding the safety and efficacy of Orgalutran (Ganirelix)® when used for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
Study Type
OBSERVATIONAL
Enrollment
711
Number of retrieved oocytes by COH based on Per stage approach
Time frame: Baseline to End of Study
Number of Serious Adverse Events
Time frame: Baseline to End of Study
Number of Unlabeled (Unexpected) Adverse Drug Reactions
Time frame: Baseline to End of Study
Number of Labeled Adverse Drug Reactions
Time frame: Baseline to End of Study
Number of Non-serious Adverse Events
Time frame: Baseline to End of Study
Number of Adverse events by drug misuse/abuse or drug-drug interaction
Time frame: Baseline to End of Study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.